Roche has delivered measurable absolute emissions reductions across Scopes 1, 2, and 3, achieved 100% sustainable electricity, and won SBTi validation for net-zero targets. But nature/biodiversity assessment is absent, water targets are intensity-only, and trade association misalignment on climate remains unaddressed.
Same formula for every company. No curve. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Targets & Commitments and Carbon Footprint — Operations (9/10, 8/10). Weakest on Nature & Biodiversity Impact and Water Impact (4/10, 5/10).
14 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Among the 11 major healthcare / pharmaceuticals brands we've scored, Roche Holding sits 6th of 11.
Score history begins 4 April 2026.
As Roche Holding's score updates, the trajectory will appear here.
We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
Roche is a Swiss multinational pharmaceuticals and diagnostics company headquartered in Basel. It ranks among the world's largest by market capitalisation, operating across prescription medicines, oncology, immunology, and in-vitro diagnostics. The company employs over 100,000 people globally with significant manufacturing and R&D footprints in Europe and North America.
Peer pharma company; enables direct emissions and governance comparison within same sector and regulatory environment.
View breakdown →Peer pharma company; comparable scale, supply chain complexity, and SBTi target ambition across life sciences.
View breakdown →Larger diversified pharma/consumer health peer; relevant for contrasting scope coverage and biodiversity commitments.
View breakdown →Peer pharma with significant UK/Europe footprint; useful for comparing governance transparency and trade association alignment.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.